Table 1.
All Participants | Major Abnormality | Any Abnormality | |||||
---|---|---|---|---|---|---|---|
Yes (N=26) | No (N=1288) | P Valuea | Yes (N=356) | No (N=958) | P Valuea | ||
Age, yr | 35.1±7.0 | 36.1±7.8 | 35.1±7.0 | 0.46 | 34.7±7.1 | 35.2±6.9 | 0.30 |
Female (%) | 47.5 | 53.9 | 47.4 | 0.51 | 41.6 | 49.7 | 0.009 |
Race (% white) | 96.3 | 92.3 | 96.4 | 0.66 | 94.7 | 96.9 | 0.13 |
Intensive treatment group (%) | 49.9 | 42.3 | 50.1 | 0.43 | 50.3 | 49.8 | 0.87 |
Primary cohort (%) | 49.7 | 38.5 | 49.9 | 0.25 | 51.4 | 49.1 | 0.45 |
Duration of diabetes, yr | 13.6±4.9 | 13.9±4.7 | 13.5±4.9 | 0.63 | 13.3±5.3 | 13.6±4.8 | 0.07 |
Current smoking (%) | 19.2 | 23.1 | 19.1 | 0.61 | 16.6 | 20.2 | 0.14 |
Body mass index, kg/m2 | 26.1±4.0 | 26.4±4.5 | 26.1±4.0 | 0.91 | 25.7±3.7 | 26.3±4.1 | 0.030 |
Body mass index ≥30 kg/m2 (%) | 13.7 | 15.4 | 13.7 | 0.80 | 11.5 | 14.5 | 0.16 |
Systolic blood pressure, mm Hg | 117±12 | 123±17 | 117±12 | 0.11 | 118±13 | 117±12 | 0.97 |
Diastolic blood pressure, mm Hg | 75±9 | 74±8 | 75±9 | 0.51 | 75±9 | 75±9 | 0.18 |
HbA1c (%) | 8.1±1.4 | 8.2±1.4 | 8.1±1.4 | 0.90 | 8.1±1.4 | 8.1±1.3 | 0.20 |
Weighted mean HbA1c (%) | 8.1±1.3 | 8.4±1.5 | 8.1±1.3 | 0.41 | 8.1±1.4 | 8.2±1.3 | 0.29 |
HDL cholesterol, mg/dL | 54±14 | 58±16 | 54±14 | 0.18 | 54±14 | 54±14 | 0.63 |
Non‐HDL cholesterol, mg/dL | 133±37 | 131±27 | 133±37 | 0.89 | 130±37 | 134±37 | 0.010 |
LDL cholesterol, mg/dL | 115±31 | 113±22 | 115±31 | 0.91 | 113±32 | 116±31 | 0.021 |
Total cholesterol, mg/dL | 187±36 | 190±25 | 187±36 | 0.43 | 183±36 | 188±36 | 0.008 |
Triglyceride, mg/dL | 91±75 | 103±86 | 90±75 | 0.86 | 87±75 | 92±75 | 0.07 |
Microalbuminuria (%) | 16.0 | 19.2 | 15.9 | 0.65 | 15.2 | 16.3 | 0.62 |
EDIC indicates Epidemiology of Diabetes Interventions and Complications (EDIC) Study; HbA1c, glycosylated hemoglobin; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein.
P value is based on chi‐square test for categorical variables and Wilcoxon rank sum test for continuous variables.